Table 5 Regression results
From: Pipeline progress and portfolio management of the top 30 pharma companies over the past two decades
Study duration | Coefficient | SE | 95% Conf. Intervall | p-value | |
|---|---|---|---|---|---|
Indication areas | 0.169 | 0.004 | 0.161 | 0.178 | 0.000 |
Company | − 0.002 | 0.002 | − 0.006 | 0.002 | 0.314 |
_cons | 0.722 | 0.054 | 0.615 | 0.829 | 0.000 |